Our results revealed that YM201636 treatment induced a striking increase in the intensity of perinuclear Rab7 (herein referring to Rab7a) immunoreactivity (Fig. 6A), resembling the perinuclear accumulation of LAMP1 in CA1 neurons of AD patients (Fig. 1A,B). The gene discussed is RAB7A; the disease is Alzheimer disease.